| Q41026009 | 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the Eur |
| Q50065204 | 2017 EACTS Guidelines on perioperative medication in adult cardiac surgery |
| Q46172217 | 49th ICAAC annual meeting: optimization of anti-infective use in the clinical setting |
| Q24091299 | A new antibiotic kills pathogens without detectable resistance |
| Q33723124 | A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study |
| Q55496455 | A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations - results of a prematurely terminated stud |
| Q34474973 | A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections |
| Q39816590 | ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections |
| Q37277083 | Acquired vancomycin resistance in clinically relevant pathogens |
| Q37333049 | Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis |
| Q26829316 | Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines |
| Q37905654 | Advances in the diagnosis and management of pediatric osteomyelitis |
| Q46103421 | Affect of linezolid in ventilator-associated pneumonia caused by MRSA. |
| Q43845142 | An interspecies extrapolation of the pharmacokinetics of telavancin, a rapidly bactericidal, concentration-dependent antibiotic |
| Q50977525 | An outbreak of heterogeneous glycopeptide-intermediate Staphylococcus aureus related to a device source in an intensive care unit. |
| Q57763234 | Antibiotic Choice May Not Explain Poorer Outcomes in Patients With Staphylococcus aureus Bacteremia and High Vancomycin Minimum Inhibitory Concentrations |
| Q36338182 | Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection |
| Q38212258 | Antibiotic resistance in cancer patients. |
| Q43237184 | Antibiotic therapy of vascular catheter-related bloodstream infections: is vancomycin the optimal choice for Staphylococcus aureus infections? |
| Q46144628 | Antimicrobial activity of tigecycline and comparative agents against clinical isolates of staphylococci and enterococci from ICUs and general hospital wards at three Swedish university hospitals |
| Q36325685 | Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci |
| Q38202581 | Antimicrobial agents, drug adverse reactions and interactions, and cancer |
| Q38052855 | Antimicrobial resistance in internal medicine wards |
| Q36968150 | Antimicrobial therapy of Staphylococcus aureus bloodstream infection |
| Q38117578 | Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations |
| Q33304458 | Approaching and analyzing a large literature on vancomycin monitoring and pharmacokinetics |
| Q84629245 | Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock |
| Q40356411 | Assessment of linezolid prescriptions in three French hospitals |
| Q42181622 | Attenuated vancomycin bactericidal activity against Staphylococcus aureus hemB mutants expressing the small-colony-variant phenotype |
| Q38202570 | Bacterial pathogens |
| Q34709457 | Bacterial toxin-triggered drug release from gold nanoparticle-stabilized liposomes for the treatment of bacterial infection |
| Q35078077 | Bactericidal activity of oxacillin and glycopeptides against Staphylococcus aureus in patients with endocarditis: looking for a relationship between tolerance and outcome |
| Q35811848 | Bacteriological profile and antimicrobial susceptibility patterns of blood culture isolates among febrile patients in Mekelle Hospital, Northern Ethiopia |
| Q38690166 | Bacteriostatic antimicrobial combination: antagonistic interaction between epsilon-viniferin and vancomycin against methicillin-resistant Staphylococcus aureus |
| Q28534516 | Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis |
| Q37186168 | Biodegradable drug-eluting poly[lactic-co-glycol acid] nanofibers for the sustainable delivery of vancomycin to brain tissue: in vitro and in vivo studies. |
| Q34981072 | Biodegradable vancomycin-eluting poly[(d,l)-lactide-co-glycolide] nanofibres for the treatment of postoperative central nervous system infection. |
| Q37147621 | Bugs versus drugs: addressing the pharmacist's challenge |
| Q36861645 | Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes |
| Q94563567 | Calculated initial parenteral treatment of bacterial infections: Skin and soft tissue infections |
| Q94563603 | Calculated parenteral initial treatment of bacterial infections: Microbiology |
| Q36439168 | Case-Control Study of Telavancin as an Alternative Treatment for Gram-Positive Bloodstream Infections in Patients with Cancer |
| Q38312543 | Ceftaroline Fosamil for the Treatment of Staphylococcus aureus Bacteremia Secondary to Acute Bacterial Skin and Skin Structure Infections or Community-Acquired Bacterial Pneumonia |
| Q37733561 | Ceftaroline for complicated skin and skin-structure infections. |
| Q34016030 | Ceftaroline: a cephalosporin with expanded Gram-positive activity |
| Q37718228 | Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens |
| Q51792973 | Central venous access in oncology: ESMO Clinical Practice Guidelines. |
| Q36349620 | Characteristics and outcomes of methicillin-resistant staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center |
| Q36898180 | Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). |
| Q48221915 | Chemistry and Biology of Teixobactin |
| Q38369089 | Chronic wound infections: the role of Pseudomonas aeruginosa and Staphylococcus aureus |
| Q35066896 | Clinical and laboratory characteristics of invasive infections due to methicillin-resistant Staphylococcus aureus isolates demonstrating a vancomycin MIC of 2 micrograms per milliliter: lack of effect of heteroresistant vancomycin-intermediate S. au |
| Q43280982 | Clinical characteristics and outcomes of diabetic patients with Staphylococcus aureus bacteremia and endocarditis |
| Q40338667 | Clinical characteristics and risk factors for mortality in patients with meningitis caused by Staphylococcus aureus and vancomycin minimal inhibitory concentrations against these isolates |
| Q33704710 | Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin |
| Q34681219 | Clinical experience with daptomycin in Europe: the first 2.5 years |
| Q38990504 | Clinical experience with the use of daptomycin in a tertiary care teaching hospital in Barcelona, Spain |
| Q37849391 | Clinical management of Staphylococcus aureus bacteraemia |
| Q43215440 | Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections |
| Q34157657 | Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children |
| Q33688646 | Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America |
| Q92546679 | Clinical practice guidelines for the provision of renal service in Hong Kong: Infection Control in Renal Service |
| Q36839693 | Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin? |
| Q41869403 | Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA. |
| Q42277926 | Combinations of cefoxitin plus other β-lactams are synergistic in vitro against community associated methicillin-resistant Staphylococcus aureus |
| Q46820461 | Community-acquired pneumonia and bacteraemia in a healthy young woman caused by methicillin-resistant Staphylococcus aureus (MRSA) carrying the genes encoding Panton-Valentine leukocidin (PVL). |
| Q37465197 | Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management |
| Q37153976 | Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy |
| Q34309620 | Comparative Efficacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia Model |
| Q37392738 | Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis |
| Q35147574 | Comparison of M.I.C.E. and Etest with CLSI agar dilution for antimicrobial susceptibility testing against oxacillin-resistant Staphylococcus spp |
| Q42169334 | Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method |
| Q37867260 | Continuing education: alternative approaches to optimizing antimicrobial pharmacodynamics in critically ill patients |
| Q37949553 | Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. |
| Q42687513 | Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus. |
| Q46558220 | Correlation of methicillin-resistant Staphylococcus aureus vancomycin minimal inhibitory concentration results by Etest and broth microdilution methods with population analysis profile: lack of Etest overestimation of the MIC. |
| Q36290499 | Correlation of vancomycin dosing to serum concentrations in pediatric patients: a retrospective database review |
| Q34726054 | Current Microbiology of Surgical Site Infections in Patients with Cancer: A Retrospective Review |
| Q35026521 | Current and novel antibiotics against resistant Gram-positive bacteria |
| Q26853465 | Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci |
| Q37873400 | Current microbiology of percutaneous endoscopic gastrostomy tube (PEG tube) insertion site infections in patients with cancer |
| Q35004264 | Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate |
| Q35782816 | Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). |
| Q36407206 | Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients |
| Q37319460 | Daptomycin in bone and joint infections: a review of the literature |
| Q44279637 | Daptomycin in complicated skin and soft tissue infections |
| Q36744825 | Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus |
| Q42215009 | Daptomycin is safe and effective for the treatment of gram-positive cocci infections in solid organ transplantation |
| Q42393393 | Daptomycin susceptibility of methicillin resistant Staphylococcus aureus (MRSA). |
| Q59135465 | Daptomycin versus teicoplanin for bloodstream infection due to methicillin-resistant Staphylococcus aureus with a high teicoplanin minimal inhibitory concentration ≥1.5 mg/L: a propensity score-based analysis |
| Q36972978 | Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates |
| Q46921060 | Daptomycin-rifampin for a recurrent MRSA joint infection unresponsive to vancomycin-based therapy |
| Q36777821 | Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections |
| Q37693931 | Daptomycin: pharmacology and clinical use. |
| Q34777837 | Decreasing the time to achieve therapeutic vancomycin concentrations in critically ill patients: developing and testing of a dosing nomogram |
| Q34667588 | Delafloxacin for the treatment of respiratory and skin infections. |
| Q36456630 | Derivation and validation of clinical prediction rules for reduced vancomycin susceptibility in Staphylococcus aureus bacteraemia |
| Q41434843 | Determination of risk factors for recurrent methicillin-resistant Staphylococcus aureus bacteremia in a Veterans Affairs healthcare system population |
| Q41915895 | Development and stability studies of novel liposomal vancomycin formulations. |
| Q38350301 | Development of novel antibacterial drugs to combat multiple resistant organisms. |
| Q64958368 | Diagnosis, prevention and treatment of haemodialysis catheter-related bloodstream infections (CRBSI): a position statement of European Renal Best Practice (ERBP). |
| Q40260585 | Does Intrawound Vancomycin Application During Spine Surgery Create Vancomycin-Resistant Organism? |
| Q43237186 | Early appropriate therapy of Gram-positive bloodstream infections: the conservative use of new drugs |
| Q97535932 | Effect of Vancomycin Loading Doses on the Attainment of Target Trough Concentrations in Hospitalized Children |
| Q36276932 | Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia |
| Q37125081 | Effects of aggregate and individual antibiotic exposure on vancomycin MICs for Staphylococcus aureus isolates recovered from pediatric patients |
| Q40024961 | Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort |
| Q34583169 | Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study |
| Q34396004 | Empiric weight-based vancomycin in intensive care unit patients with methicillin-resistant Staphylococcus aureus bacteremia. |
| Q34602379 | Endophthalmitis caused by Enterococcus faecalis: clinical features, antibiotic sensitivities, and outcomes |
| Q36930855 | Epidemiology and economic impact of meticillin-resistant Staphylococcus aureus: review and analysis of the literature |
| Q35593072 | Epidemiology and prognosis of coagulase-negative staphylococcal endocarditis: impact of vancomycin minimum inhibitory concentration |
| Q26823518 | European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid |
| Q45951342 | Evaluation of a pediatric continuous-infusion vancomycin therapy guideline. |
| Q42072065 | Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus |
| Q64233313 | Evaluation of efficacy and nephrotoxicity during vancomycin therapy: A retrospective study in China |
| Q41789314 | Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin |
| Q41907664 | Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro |
| Q41429045 | Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods |
| Q42948108 | Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus |
| Q93260059 | Evidence from an In Vitro Study: Is Oxacillin Plus Vancomycin a Better Choice for Heteroresistant Vancomycin-Intermediate Staphylococcus aureus? |
| Q46105589 | Extremely low excretion of daptomycin into breast milk of a nursing mother with methicillin-resistant Staphylococcus aureus pelvic inflammatory disease |
| Q84343347 | Factors influencing the clinical outcome of methicillin-resistant Staphylococcus aureus bacteraemia |
| Q33642100 | Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypes |
| Q41016957 | First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia |
| Q36439147 | Fosfomycin plus β-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus |
| Q46231683 | Frequency of occurrence and daptomycin susceptibility rates of Gram-positive organisms causing bloodstream infections in cancer patients |
| Q22305769 | Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSA |
| Q35666429 | Generic vancomycin enriches resistant subpopulations of Staphylococcus aureus after exposure in a neutropenic mouse thigh infection model |
| Q28354064 | Genome-Wide Identification of Antimicrobial Intrinsic Resistance Determinants in Staphylococcus aureus |
| Q92320936 | Genomic insights on heterogeneous resistance to vancomycin and teicoplanin in Methicillin-resistant Staphylococcus aureus: A first report from South India |
| Q31148610 | Genotypically different clones of Staphylococcus aureus are diverse in the antimicrobial susceptibility patterns and biofilm formations |
| Q37413851 | Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom |
| Q36315377 | Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA). |
| Q36409465 | Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. |
| Q36452459 | Health care-associated endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin |
| Q36692468 | Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance |
| Q39756833 | High MICs for Vancomycin and Daptomycin and Complicated Catheter-Related Bloodstream Infections with Methicillin-Sensitive Staphylococcus aureus |
| Q35806306 | High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus |
| Q35980091 | High vancomycin MIC and complicated methicillin-susceptible Staphylococcus aureus bacteremia |
| Q34454418 | High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis |
| Q37255571 | Hospital-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) in Italy |
| Q38569678 | How to use vancomycin optimally in neonates: remaining questions |
| Q39486464 | Immunomodulatory effects of recombinant lactoferrin during MRSA infection. |
| Q37055102 | Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations |
| Q83172498 | Impact of administration of vancomycin or linezolid to critically ill patients with impaired renal function |
| Q38104279 | Impact of community-associated methicillin resistant Staphylococcus aureus on HIV-infected patients |
| Q36287998 | Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. |
| Q44122816 | Impact of the introduction of an automated microbiologic system on the clinical outcomes of bloodstream infections caused by Enterobacteriaceae strains |
| Q40261278 | Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia |
| Q36515260 | Implementation of antibiotic management teams in Belgian hospitals |
| Q37800310 | Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia |
| Q41901707 | In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis |
| Q35598497 | In vitro activities of daptomycin-, vancomycin-, and teicoplanin-loaded polymethylmethacrylate against methicillin-susceptible, methicillin-resistant, and vancomycin-intermediate strains of Staphylococcus aureus |
| Q40252885 | In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients |
| Q33876626 | In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates |
| Q42215430 | In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients |
| Q46867668 | In vitro antimicrobial activity of telavancin against methicillin-resistant Staphylococcus aureus clinical isolates from Japan (2006). |
| Q35063799 | In vitro bactericidal activity of 4- and 5-chloro-2-hydroxy-N-[1-oxo-1-(phenylamino)alkan-2-yl]benzamides against MRSA. |
| Q42539833 | In vitro evaluation of antibiotics for methicillin-resistant Staphylococcus aureus from north India |
| Q40326741 | In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus |
| Q41066970 | Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period |
| Q42931892 | Increased vancomycin minimum inhibitory concentration among Staphylococcus aureus isolates in Malaysia |
| Q37156698 | Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains |
| Q42042890 | Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin |
| Q46826194 | Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia |
| Q41915074 | Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006. |
| Q37190789 | Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007. |
| Q36666985 | Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice |
| Q40600332 | Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010. |
| Q34591873 | Is vancomycin MIC creep a worldwide phenomenon? Assessment of S. aureus vancomycin MIC in a tertiary university hospital |
| Q36538707 | Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity |
| Q46728767 | Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies |
| Q36089510 | Local Intramedullary Delivery of Vancomycin Can Prevent the Development of Long Bone Staphylococcus aureus Infection |
| Q36025384 | Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective. |
| Q55081351 | Management Practices for Methicillin-Resistant Staphylococcus aureus Bacteremia by Adult Infectious Diseases Physicians. |
| Q41665025 | Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure |
| Q37700552 | Management of antibiotic resistance in the intensive care unit setting |
| Q37899198 | Management of gram-positive bacterial infections in patients with cancer |
| Q37156709 | Management of methicillin-resistant Staphylococcus aureus bacteremia |
| Q37675798 | Management of methicillin-resistant Staphylococcus aureus pneumonia |
| Q38018983 | Management of ventilator-associated pneumonia: epidemiology, diagnosis and antimicrobial therapy. |
| Q41340004 | Managing skin and soft-tissue infection and nosocomial pneumonia caused by MRSA: a 2014 follow-up survey |
| Q36565462 | Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall |
| Q26828604 | Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones |
| Q80585586 | Medical treatment of endocarditis |
| Q42544277 | Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design |
| Q42986026 | Methicillin resistance and vancomycin heteroresistance in Staphylococcus aureus in cystic fibrosis patients |
| Q35827804 | Methicillin-resistant Staphylococcus aureus (MRSA) catheter-related bacteraemia in haemodialysis patients |
| Q37344700 | Methicillin-resistant Staphylococcus aureus bacteraemia and mortality in a teaching hospital |
| Q38230203 | Methicillin-resistant Staphylococcus aureus pneumonia in adults |
| Q28235095 | Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey |
| Q34453707 | Meticillin-resistant Staphylococcus aureus |
| Q36870930 | Microbiological and genotypic analysis of methicillin-resistant Staphylococcus aureus bacteremia |
| Q36328966 | Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains |
| Q50908013 | Molecular and phenotypic evidence for the spread of three major methicillin-resistant Staphylococcus aureus clones associated with two characteristic antimicrobial resistance profiles in China. |
| Q36747581 | Molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates in urban Detroit |
| Q34146036 | Molecular typing and phenotype characterization of methicillin-resistant Staphylococcus aureus isolates from blood in Taiwan |
| Q46255695 | Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus |
| Q36667027 | Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment |
| Q37588890 | Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus |
| Q41873909 | Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus |
| Q36218244 | Nosocomial MRSA infection in vascular surgery patients: impact on patient outcome. |
| Q33596888 | Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method |
| Q91742543 | Novel antibiotics effective against gram-positive and -negative multi-resistant bacteria with limited resistance |
| Q37362652 | Novel targets in the management of pneumonia |
| Q57815402 | Novel vancomycin-peptide conjugate as potent antibacterial agent against vancomycin-resistant |
| Q33939095 | Observation of "seesaw effect" with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains |
| Q89521993 | Occurrence of cross-resistance and β-lactam seesaw effect in glycopeptide-, lipopeptide- and lipoglycopeptide-resistant MRSA correlates with membrane phosphatidylglycerol levels |
| Q45183500 | Optimizing delivery of care for patients with MRSA infection: focus on transitions of care |
| Q38434265 | Oritavancin: A Long-Half-Life Lipoglycopeptide |
| Q44028701 | Outcome of patients with meticillin-resistant Staphylococcus aureus bacteraemia at an Emergency Department of a medical centre in Taiwan. |
| Q33997671 | Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs |
| Q38627072 | PEGylated liposome encapsulation increases the lung tissue concentration of vancomycin |
| Q41855744 | Performance of the Oxoid M.I.C.Evaluator Strips compared with the Etest assay and BSAC agar dilution |
| Q36903680 | Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus |
| Q36777850 | Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections |
| Q42076409 | Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia |
| Q37095512 | Pharmacodynamics of vancomycin in elderly patients aged 75 years or older with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia |
| Q53654914 | Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries. |
| Q38664871 | Pharmacokinetics and pharmacodynamics in antibiotic dose optimization. |
| Q36735202 | Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus. |
| Q38066654 | Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia |
| Q36528796 | Phenotypic and Genotypic Characterization of Animal-Source Salmonella Heidelberg Isolates |
| Q88447041 | Population Pharmacokinetic Model for Vancomycin Used in Open Heart Surgery: Model-Based Evaluation of Standard Dosing Regimens |
| Q51063904 | Potent in vitro synergism of fusidic acid (FA) and berberine chloride (BBR) against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). |
| Q42154638 | Precision of vancomycin and daptomycin MICs for methicillin-resistant Staphylococcus aureus and effect of subculture and storage |
| Q34756833 | Predicting high vancomycin minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus bloodstream infections |
| Q36037687 | Predicting risk for death from MRSA bacteremia |
| Q35270746 | Prediction of failure in vancomycin-treated methicillin-resistant Staphylococcus aureus bloodstream infection: a clinically useful risk stratification tool |
| Q34989352 | Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation |
| Q37356506 | Predictors and clinical outcomes of persistent methicillin-resistant Staphylococcus aureus bacteremia: a prospective observational study. |
| Q46434907 | Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia |
| Q35940556 | Predictors of mortality in Staphylococcus aureus Bacteremia |
| Q51906645 | Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: the role of empiric antibiotic therapy. |
| Q44890185 | Prevalence of isolates with reduced glycopeptide susceptibility in orthopedic device-related infections due to methicillin-resistant Staphylococcus aureus. |
| Q36501398 | Prevalence, persistence, and microbiology of Staphylococcus aureus nasal carriage among hemodialysis outpatients at a major New York Hospital |
| Q37823200 | Prevention and management of catheter-related infection in hemodialysis patients |
| Q37697213 | Prior vancomycin use is a risk factor for reduced vancomycin susceptibility in methicillin-susceptible but not methicillin-resistant Staphylococcus aureus bacteremia. |
| Q33704733 | Real-time PCR testing for mecA reduces vancomycin usage and length of hospitalization for patients infected with methicillin-sensitive staphylococci |
| Q64131294 | Recomendaciones GEIPC-SEIMC y GTEI-SEMICYUC para el tratamiento antibiótico de infecciones por cocos grampositivos en el paciente crítico |
| Q33883752 | Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function |
| Q37982066 | Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC Creep'): implications for therapy |
| Q24646677 | Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications |
| Q36667211 | Reduced vancomycin susceptibility in an in vitro catheter-related biofilm model correlates with poor therapeutic outcomes in experimental endocarditis due to methicillin-resistant Staphylococcus aureus |
| Q47703908 | Relationship between agr dysfunction and reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus causing bacteraemia. |
| Q45279504 | Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia |
| Q36870858 | Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin |
| Q38780029 | Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia |
| Q35598479 | Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial |
| Q27011138 | Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections |
| Q64131298 | Resumen de las recomendaciones GEIPC-SEIMC y GTEI-SEMICYUC para el tratamiento antibiótico de infecciones por cocos gram positivos en el paciente crítico |
| Q37605511 | Retrospective review of the use of daptomycin for diabetic foot infections |
| Q80215627 | Reversion of resistance in relapsing infection caused by a glycopeptide-intermediate methicillin-resistant Staphylococcus aureus isolate |
| Q35014131 | Risk factors and management of Gram-positive bacteraemia |
| Q40136604 | Risk factors for mortality in patients with Staphylococcus aureus bloodstream infection |
| Q42743418 | Role of daptomycin in the treatment of infections in patients with hematological malignancies |
| Q37058032 | Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection |
| Q45936598 | Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy. |
| Q54559786 | Safety of daptomycin in patients receiving hemodialysis. |
| Q35913176 | Setting and revising antibacterial susceptibility breakpoints |
| Q33883648 | Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations |
| Q37358940 | Should higher vancomycin trough levels be targeted for invasive community-acquired methicillin-resistant Staphylococcus aureus infections in children? |
| Q38045269 | Significant publications on infectious diseases pharmacotherapy in 2011. |
| Q36894458 | Staphylococci. |
| Q58694105 | Staphylococcus aureus bacteremia in a secondary level Spanish hospital: clinical implications of high vancomycin MIC |
| Q27002517 | Strategies for appropriate antibiotic use in intensive care unit |
| Q40362524 | Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin |
| Q37602845 | Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions |
| Q36364048 | TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections |
| Q37983130 | Tedizolid (TR-701): a new oxazolidinone with enhanced potency |
| Q42049579 | Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. |
| Q41445957 | Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis |
| Q38048845 | Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies. |
| Q35905561 | Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA). |
| Q39686295 | Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation |
| Q34572923 | Telavancin: a new lipoglycopeptide with multiple mechanisms of action |
| Q37463589 | Telavancin: a novel lipoglycopeptide antibiotic |
| Q36277424 | The association between vancomycin trough concentrations and acute kidney injury in the neonatal intensive care unit |
| Q37981103 | The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. |
| Q38131442 | The current spectrum of infection in cancer patients with chemotherapy related neutropenia. |
| Q37347361 | The effect of age and weight on vancomycin serum trough concentrations in pediatric patients |
| Q37250567 | The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas |
| Q38068293 | The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties. |
| Q91915067 | The prevalence of community-associated methicillin-resistant Staphylococcus aureus among outpatient children in a tertiary hospital: A prospective observational study in Riyadh, Saudi Arabia |
| Q36779557 | The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus |
| Q36148828 | The safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus aureus: a meta-analysis |
| Q34910366 | Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists |
| Q43834023 | Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. |
| Q42743427 | Tolerance and heteroresistance in Gram-positive microorganisms |
| Q42914487 | Treatment of Infections Caused By Antimicrobial-Resistant Gram-Positive Bacteria |
| Q36363239 | Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia with Ceftaroline Fosamil in a Patient with Inhalational Thermal Injury |
| Q81323178 | Treatment of community-associated methicillin-resistant Staphylococcus aureus |
| Q81756064 | Treatment of community-associated methicillin-resistant Staphylococcus aureus |
| Q35959558 | Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin |
| Q38428770 | Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents |
| Q37533560 | Treatment options for skin and soft tissue infections caused by meticillin-resistant Staphylococcus aureus:oralvs.parenteral; home vs. hospital |
| Q37681564 | Treatment strategies for infective endocarditis. |
| Q37600389 | Treatments for skin and soft-tissue and surgical site infections due to MDR Gram-positive bacteria |
| Q34108614 | Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus. |
| Q42743429 | Update of antimicrobial resistance in Gram-positive microorganisms |
| Q46274310 | Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections |
| Q44436591 | Use of daptomycin in complicated cases of infective endocarditis |
| Q38164663 | Use of daptomycin to treat infections with methicillin-resistant Staphylococcus aureus isolates having vancomycin minimum inhibitory concentrations of 1.5 to 2 μg/mL. |
| Q33881584 | Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections |
| Q36888003 | Vancomycin 24-Hour Area under the Curve/Minimum Bactericidal Concentration Ratio as a Novel Predictor of Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia |
| Q36757645 | Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia |
| Q35689318 | Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization |
| Q61814412 | Vancomycin MIC Distribution among Methicillin-Resistant . Is Reduced Vancomycin Susceptibility Related To MIC Creep? |
| Q42871030 | Vancomycin MIC Susceptibility Testing of Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Isolates: A Comparison Between Etest® and an Automated Testing Method |
| Q54392892 | Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem? |
| Q41428954 | Vancomycin MIC for methicillin-resistant coagulase-negative Staphylococcus isolates: evaluation of the broth microdilution and Etest methods. |
| Q43117809 | Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years |
| Q42098506 | Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005 |
| Q43202070 | Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used |
| Q48575528 | Vancomycin MICs of the resistant mutants of S. aureus ATCC43300 vary based on the susceptibility test methods used |
| Q34967980 | Vancomycin Minimum Inhibitory Concentration for Methicillin-Resistant Staphylococcus aureus Infections; Is There Difference in Mortality Between Patients? |
| Q42706371 | Vancomycin bactericidal activity as a predictor of 30-day mortality in patients with methicillin-resistant Staphylococcus aureus bacteremia |
| Q42535624 | Vancomycin dosage regimens for pediatric patients |
| Q33926436 | Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software. |
| Q46457973 | Vancomycin flush as antibiotic prophylaxis for early catheter-related infections: a cost-effectiveness analysis |
| Q36847287 | Vancomycin for treatment of invasive, multi-drug resistant Staphylococcus aureus infections |
| Q33945397 | Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections. |
| Q35879117 | Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia |
| Q42177195 | Vancomycin levels are frequently subtherapeutic during continuous venovenous hemodialysis (CVVHD). |
| Q37072057 | Vancomycin ototoxicity: a reevaluation in an era of increasing doses |
| Q34405301 | Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysis |
| Q34433066 | Vancomycin revisited - 60 years later |
| Q42153532 | Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates |
| Q40483972 | Vancomycin tolerance, a potential mechanism for refractory gram-positive bacteremia observational study in patients with cancer |
| Q35203343 | Vancomycin tolerant, methicillin-resistant Staphylococcus aureus reveals the effects of vancomycin on cell wall thickening |
| Q33844670 | Vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations: study protocol for a phase IIB randomized controlled trial |
| Q42913340 | Vancomycin, what else? |
| Q33617737 | Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? |
| Q41885249 | Vancomycin-eluting niosomes: a new approach to the inhibition of staphylococcal biofilm on abiotic surfaces |
| Q36839712 | Vancomycin: does it still have a role as an antistaphylococcal agent? |
| Q38542797 | Vancomycin: the tale of the vanquisher and the pyrrhic victory. |
| Q37365775 | What's new on the antimicrobial horizon? |
| Q84028196 | [Daptomycin in the context of antimicrobial resistance in Gram-positive bacteria] |
| Q84028199 | [Daptomycin therapy in patients with bacteremia] |
| Q37544579 | β-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone. |